相关实验视频
Updated: May 26, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.8K
梨油:其抗糖尿病潜力的近期进展
Dorji Drakpa1, Taniya Paul1, Sukriti Chakrabarty1
1School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, 144001, India.
Current medical science
|February 25, 2025
概括
富含单不和脂肪酸 (MUFA) 的梨油可以改善糖尿病患者的血糖和胆固醇水平. 然而,它的成分因梨类型而异,影响其健康益处.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
背景情况:
- 饮食显著影响胰岛素抵抗和糖尿病.
- 脂肪酸类型严重影响胰岛素敏感性.
- 高脂肪和高碳水化合物饮食是代谢功能障碍的主要原因.
研究的目的:
- 审查富含单不和脂肪酸 (MUFA) 的梨油的代谢益处.
- 评估梨油对血糖控制和脂质代谢的影响.
- 探索梨品种的变化如何影响油的成分和治疗性质.
主要方法:
- 对梨油代谢作用的实验和临床研究的分析.
- 单不和脂肪酸 (MUFA) 对胰岛素敏感性,脂质概况和代谢健康的影响的审查.
- 检查诸如水果质量,成熟度和种类差异等因素对梨油的特性.
主要成果:
- 梨油显示出改善血糖控制和脂质代谢的潜力.
- 益处可能延伸到糖尿病和高胆固醇血症患者.
- 梨油成分在各品种之间存在显著的差异 (例如,哈斯,里德,埃廷格,富尔特),影响其治疗效果.
结论:
- 梨油中的高单不和脂肪酸 (MUFA) 含量提供了有希望的代谢优势.
- 需要进一步的研究来规范梨油的治疗用途.
- 必须考虑依赖种类的组成差异,以获得最佳的应用.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142
Dipeptidyl Peptidase 4 Inhibitors
162
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
162
Diabetes: Symptoms, Diagnosis, and Complications
495
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
495
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291

